Angelini Pharma is reportedly eyeing Catalyst Pharmaceuticals as part of a strategy to broaden its international reach. Sources close to the deal say the Italian company is in early talks, weighing a potential purchase that could reshape its product portfolio and market presence.

While the exact value of the transaction remains undisclosed, industry observers note that a purchase of Catalyst Pharmaceuticals would inject substantial R&D assets into Angelini’s pipeline. The move signals a shift toward leveraging specialty drug segments that have shown robust growth in recent years today.

Angelini’s interest comes amid a broader trend of consolidation in the pharma sector, where firms are seeking to accelerate innovation through acquisitions rather than organic growth alone. If the deal proceeds, it would position Angelini as a more global player with an expanded therapeutic footprint in the near term.

The next steps will involve due diligence and regulatory scrutiny, with potential antitrust reviews depending on the combined market share. Investors will watch how the valuation aligns with Angelini’s current earnings and whether the acquisition will generate immediate shareholder value.